Gonadorelin (Native GnRH)

What is Gonadorelin?

Gonadorelin is the pharmacological name for synthetic native GnRH (Gonadotropin-Releasing Hormone), a 10-amino-acid decapeptide that exactly replicates the sequence of the endogenous hypothalamic factor. Under normal physiological conditions, the hypothalamus releases GnRH in a pulsatile manner every 60-120 minutes; this pulsatility is the key to its action.

Unlike synthetic GnRH analogs (such as leuprolide or buserelin), gonadorelin introduces no modifications to the peptide chain. This fidelity to the native sequence is precisely what determines its pharmacological profile: it requires frequent dosing (BID or TID) but produces physiological hormonal stimulation without the desensitization effects that characterize long-acting analogs.

Important: The use of gonadorelin as support in hormone replacement therapies (TRT) is off-label. The information on this page is exclusively educational and does not constitute medical advice.

Mechanism of Action

Gonadorelin acts on GnRHR receptors (G-protein coupled receptors) located in the gonadotropic cells of the anterior pituitary.

Signaling cascade:

1. Binding to GnRHR → activation of the Gq/PLC/IP3 pathway → elevation of intracellular calcium.
2. Pulsatile release of LH (luteinizing hormone) and FSH (follicle-stimulating hormone) from the pituitary.
3. LH acts on testicular Leydig cells → synthesis and secretion of testosterone.
4. FSH acts on Sertoli cells → maintenance of spermatogenesis.

The continuous stimulation paradox: The physiological key to GnRH is pulsatility. When administered continuously rather than pulsatilely, GnRHR receptors desensitize and a paradoxical suppression of LH/FSH occurs (pituitary down-regulation). This principle is exactly what depot GnRH analogs exploit in oncology (leuprolide) to suppress testosterone in prostate cancer. Gonadorelin at pulsatile doses does the opposite: it maintains or restores the hypothalamic-pituitary-gonadal axis.

Comparison with HCG: HCG (human chorionic gonadotropin) acts directly on LH receptors in Leydig cells, completely bypassing the pituitary axis. Gonadorelin acts higher up in the cascade (at the pituitary level), which theoretically generates a more physiological signal with less tendency for LH receptor desensitization. HCG, however, has the practical advantage of requiring fewer injections (2-3 times per week vs. BID/TID).

Reported Research Protocol

Vial reconstitution (2 mg):

• Add 2.0 mL of bacteriostatic water → concentration 1 mg/mL (1,000 mcg/mL).
• For 100 mcg → 0.10 mL (10 units on a U-100 syringe).
• Post-reconstitution shelf life: up to 14 days refrigerated (shorter than most peptides).

Note on timing: Given the half-life of only 2-10 minutes, regular spacing of doses (e.g., morning and evening) is more critical than with long-half-life peptides.

Effects Reported in Literature

• Physiological stimulation of LH and FSH: Maintenance of the hypothalamic-pituitary-gonadal axis in contexts of exogenous suppression (TRT with exogenous testosterone).
• Maintenance of spermatogenesis: The preserved FSH signal supports Sertoli cell function and sperm production, a relevant benefit for men on TRT who wish to preserve fertility.
• Lower risk of LH receptor desensitization compared to HCG, since the signal originates from the pituitary rather than direct gonadal stimulation.
• Diagnosis of pituitary dysfunction: In approved medical context, used to assess pituitary responsiveness to GnRH stimulus.

Described Adverse Effects

• Headache: Reported especially in early phases; generally transient.
• Nausea and gastrointestinal discomfort: Uncommon; more frequently reported with higher doses.
• Facial flushing: Mild vasodilatory effect associated with LH release.
• Pituitary desensitization from overdosing: If doses are excessively high or frequency is inadequate, it can paradoxically suppress LH/FSH (GnRH analog effect). This risk underscores the importance of pulsatile spacing.
• Local injection site reactions: Mild erythema or inflammation, as with any SC injection.

Storage

Reconstituted gonadorelin has a shorter shelf life than most research peptides. Plan vial use within two weeks of reconstitution.

Legal disclaimer: This content is for educational purposes only. Not medical advice. Always consult a healthcare professional.

Reported protocol (research reference)